Evaluate the Clinical Outcome of Nanoparticle Albumin-bound Paclitaxel on Breast Cancer Treatment: A Systematic Review and Meta-analysis

Background and aim: Nanoparticle albumin-bound paclitaxel can have a higher response rate than paclitaxel in women with metastatic breast cancer. Therefore, the present study was conducted to evaluate the clinical outcome of nanoparticle albumin-bound paclitaxel on breast cancer treatment. Material and methods: All articles published in international databases such as PubMed, Scopus, Science Direct, ISI Web of knowledge, and Embase between March 2016 and August 2022 included. 95% confidence interval (CI) for odds ratio and risk ratio with fixed effect modal and Mantel-Haenszel were calculated. Data analysis was performed using STATA.V16 software. Results: In the initial review, the abstracts of 249 studies were reviewed, two authors reviewed the full text of 42 studies, and finally, nine studies were selected. The odds ratio of the Overall response rate in breast cancer patients between nab-paclitaxel and the control group was 0.22 (95% CI, 0.04 to 0.41; p=0.02) in breast cancer patients with been treated with neoadjuvant nab-paclitaxel, Overall response rate was higher. Conclusions: Based on the findings of the present meta-analysis, complete pathological response and overall response rate were higher for the neoadjuvant nab-paclitaxel than conventional taxane regimens.